Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 14/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440916 | 0.84 | HCAR3 (0.57) | HCAR3MAPTKMT2APKMNPC1 | |
| SCHEMBL2251103 | 0.82 | KMT2A (0.61) | HCAR3MAPTKMT2APKMMEN1 | |
| Methyl Alcohol SCHEMBL28856375 | 0.78 | HCAR3 (0.51) | HCAR3MAPTKMT2APKMNPC1 | |
| SCHEMBL28799465 | 0.76 | KAT2B (0.55) | MAPTKMT2AMEN1NPC1 | |
| SCHEMBL14106469 | 0.76 | KMT2A (0.56) | MAPTKMT2AMEN1NPC1RECQL | |
| SCHEMBL990061 | 0.76 | MAPT (0.44) | HCAR3MAPTKMT2APKMMEN1 | |
| SCHEMBL10249376 | 0.76 | KAT2B (0.61) | HCAR3MAPTNPC1 | |
| SCHEMBL1496476 | 0.75 | ALDH1A1 (0.55) | MAPTKMT2APKMMEN1NPC1 | |
| SCHEMBL989316 | 0.75 | HCAR3 (0.59) | CES2CES1HCAR3MAPTRECQL | |
| SCHEMBL400483 | 0.75 | HCAR3 (0.62) | HCAR3MAPTKMT2APKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | CES2 3750/4885CES1 2629/4885HCAR3 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.